Saptarsi M. Haldar, MD, is Senior Vice President and Global Head of Research Biology at Genentech, based out of the headquarters in South San Francisco. He is also a Visiting Professor at The Gladstone Institutes and University of California San Francisco (UCSF). He received his BS from Cornell University and MD from Johns Hopkins University School of Medicine. He completed an Internal Medicine residency at Johns Hopkins followed by a Fellowship in Cardiovascular Disease at Brigham and Women’s Hospital, Harvard Medical School. After training in the laboratory of Dr. Mukesh Jain, he was on faculty at Case Western Reserve University School of Medicine prior to joining Gladstone/UCSF. Dr. Haldar’s research group has uncovered novel gene regulatory signaling mechanisms that govern cardiovascular and metabolic homeostasis and has elucidated how these processes go awry in disease. His work has provided therapeutically relevant insights for a broad range of conditions such as heart failure, metabolic disorders, muscular dystrophy, and vascular disease. Dr. Haldar is a co-founder of Tenaya Therapeutics, a San Francisco based company launched in 2016 whose goal is to develop novel therapies for heart failure. He was the head of Cardiovascular/Metabolic Research at Amgen from 2018-2025. While at Amgen, he completed an MBA from The Wharton School, University of Pennsylvania. He joined Genentech in 2025 where he oversees research across all therapeutic areas (oncology, immunology, neurology, cardiovascular, metabolic, renal, ophthalmology, and infectious disease).